Weekly update Companies AI-cruiter Recruiting

BlueJay Therapeutics

Founded: 2019

Location: San Francisco, CA

Employee range: 11 - 50

Clinical stage: Clin1b

Therapy area: Hepatitis B

Drug types: INF

Lead product: BJT-778

Product link: https://bluejaytx.com/#pipeline

Funding: $41M B Aug 2022

Investors: Arkin Bio Ventures, Synergenics LLC, RiverVest Venture Partners, Yonjin Capital, Octagon Capital, InnoPinnacle International

bluejaytx.com

linkedin.com

job board

Short description:

Monoclonal Antibody, Small Molecule

Drug notes:

Also Clin1 hepatitis D; BJT-628 Clin0 hepatitis B

Long description:

BlueJay Therapeutics is developing therapeutics for the treatment of infectious diseases. In 2019, 296M people worldwide were living with hepatitis B. With decades of experience in HBV, virology, immunology and liver diseases, BlueJay is identifying and developing highly differentiated assets that offer the greatest therapeutic potential with the lowest risk for patients. BlueJay’s assets currently consist of antibody biologics and small molecules. BlueJay’s lead candidate, BJT-778, a best-in-class monoclonal antibody against hepatitis B surface antigen, recently received regulatory clearance to initiate clinical studies for patients with chronic hepatitis B. BJT-778 may help to reconstitute a patient’s antiviral immunity by neutralizing and clearing hepatitis B virions.

Jobs:

Main

Contact: recruit@workinbiotech.com